Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression

• Published in: Urologic oncology 2018-08, Vol.36 (8), p.366.e1-366.e9
• Main Authors: Peng, Shengmeng, Du, Tao, Wu, Wanhua, Chen, Xianju, Lai, Yiming, Zhu, Dingjun, Wang, Qiong, Ma, Xiaoming, Lin, Chunhao, Li, Zean, Guo, Zhenghui, Huang, Hai
• Format: Article
• Language: English
• Subjects: Oncomine; Prognosis; Prostate cancer; Serine protease inhibitor family G1 (SERPING1); TCGA
• ISSN: 1078-1439; 1873-2496
• DOI: 10.1016/j.urolonc.2018.05.021

The aim of this study was to investigate the associations of serine proteinase inhibitor family G1 (SERPING1) down-regulation with poor prognosis in patients with prostate cancer (PCa). Furthermore, we aim to find more novel and effective PCa molecular markers to provide an early screening of PCa, distinguish patients with aggressive PCa, predict the prognosis, or reduce the economic burden of PCa. SERPING1 protein expression in both human PCa and normal prostate tissues was detected by immunohistochemical staining, which intensity was analyzed in association with clinical pathological parameters such Gleason score, pathological grade, clinical stage, tumor stage, lymph node metastasis, and distant metastasis. Moreover, we used The Cancer Genome Atlas (TCGA) Database, Taylor Database, and Oncomine dataset to validate our immunohistochemical results and investigated the value of SERPING1 in PCa at mRNA level. Kaplan-Meier analysis and Cox regression analysis were performed to evaluate the relationship between SERPING1 and prognosis of patients with PCa. The outcome showed that SERPING1 was expressed mainly in cytoplasm of grand cells of prostate tissue and was significantly expressed less in PCa (P